New CMMI payment model on ESRD announced
The Centers for Medicare & Medicaid Services today finalized a new Center for Medicare and Medicaid Innovation payment model aimed at transforming kidney care to ensure patients with chronic kidney disease have access to high quality, coordinated care.
The End-Stage Renal Disease Treatment Choices model will be mandatory for dialysis facilities and managing clinicians in certain areas of the country beginning Jan. 1, and test whether greater use of home dialysis and kidney transplantation for Medicare beneficiaries with ESRD reduce expenditures while preserving or enhancing quality of care.
The model’s payment adjustments will begin in January and run through June 30, 2027.
Related News Articles
Chairperson's File
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
The AHA expressed support Nov. 3 for the bipartisan Home Health Stabilization Act (H.R. 5142), legislation that would establish a two-year pause on planned…
Headline
The AHA and a coalition of organizations yesterday urged House and Senate leaders to pass the Reforming and Enhancing Sustainable Updates to Laboratory Testing…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…